A Case of Immunoglobulin Therapy for Pure Red Cell Aplasia Induced by Parvovirus B19.
10.5045/kjh.2007.42.3.283
- Author:
Jae Hyun CHO
1
;
Won Sub CHOI
;
Kyung Rim HUH
;
Ji Eon WON
;
Young Kyung LEE
;
Dae Young ZANG
;
Hyo Jung KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Korea. hemonc@hallym.or.kr
- Publication Type:Case Report
- Keywords:
Human parvovirus B19;
Pure red-cell aplasia;
Immunoglobulins
- MeSH:
Adult;
Anemia;
Bone Marrow;
Dizziness;
Drug Therapy;
Female;
Headache;
Humans;
Immunization, Passive*;
Immunocompromised Host;
Immunoglobulin M;
Immunoglobulins*;
Lymphoma, Non-Hodgkin;
Parvovirus B19, Human;
Parvovirus*;
Polymerase Chain Reaction;
Red-Cell Aplasia, Pure*;
Reticulocyte Count;
T-Lymphocytes
- From:Korean Journal of Hematology
2007;42(3):283-287
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Human parvovirus B19 infection could be manifested as pure red cell aplasia or chronic anemia in immunocompromised host. The patient was 35-year-old female who had been diagnosed as non-Hodgkin lymphoma, peripheral T-cell unspecified type and had been performed chemotherapy. She complained headache and dizziness that was found to a marked drop in hemoglobin (3.2g/dL). A bone marrow aspiration revealed findings consistent with erythroid hypoplasia with maturation arrest. Serum parvovirus B19 PCR and anti parvovirus B19 IgM were positive. After immunoglobulin therapy, it was leading to a marked increase in reticulocyte count and corresponding rise in hemoglobin. To our knowledge, this is the first report to use immunoglobulin in an adult cancer patient with pure red-cell aplasia. Human parvovirus B19 infection should be considered in immunocompromised cancer patients with red cell aplasia and early use of immunoglobulins would be helpful in resolution of anemia and not to delay planned chemotherapy.
